

► GRIN Therapeutics*(FDA , Orphan)*

The FDA Grants Orphan Drug Designation to GRIN Therapeutics' Radiprodil for Treating GRIN-Related Neurodevelopmental Disorder

► BioArctic*(FDA , Orphan)*

The FDA Grants Orphan Drug Designation to BioArctic's Exidavnemab for Treating Multiple System Atrophy

► Johnson & Johnson*(FDA , Approval)*

J&J's TREMFYA (Guselkumab) Receives FDA Approval for Adults With Moderately to Severely Active Crohn's Disease

► Henlius*(FDA , Orphan)*

The FDA granted Orphan Drug Designation to Henilu's Anti-HER2 mAb HLX22 for the Treatment of Gastric Cancer

► Anuncia Medical*(FDA)*

Anuncia Medical Received FDA Breakthrough Device Designation for ReFlow EVD, a Device for External Ventricular Drains to Manage Brain Swelling and Elevated Intracranial Pressure





●▶ **Novartis** *(FDA , Approval)*

Novartis's Fabhalta was Approved by the FDA as the First and only Treatment for C3 Glomerulopathy

●▶ **Formosa Pharmaceuticals and Cipla** *(Collaboration)*

Formosa Pharmaceuticals and Cipla Partnered for the Commercialization of Clobetasol Propionate Ophthalmic Suspension to Treat Postoperative Inflammation and Pain following Ocular Surgery

●▶ **Syneron Bio and AstraZeneca** *(Collaboration)*

Syneron Bio Announced a Strategic Collaboration with AstraZeneca to Develop Macrocyclic Peptides for the Treatment of Chronic Diseases

●▶ **Innovent and HUTCHMED** *(Positive Data)*

Innovent and HUTCHMED Announced that their Phase 2/3 FRUSICA-2 Study of Sintilimab Plus Fruquintinib Met its Primary Endpoint in Advanced RCC

●▶ **AstraZeneca and Alteogen** *(Collaboration)*

AstraZeneca and Alteogen have Signed a Commercialization Agreement for ALT-B4, a Hyaluronidase Used in Various Oncology Assets

